Who is sponsoring NCT02695381?

NCT02695381 is sponsored by MEDRx USA, Inc..

What drugs are being tested in NCT02695381?

Interventions in NCT02695381: Etodolac-lidocaine topical patch, Placebo.

What condition does NCT02695381 study?

NCT02695381 studies Acute Delayed Onset Muscle Soreness (DOMS).

Is NCT02695381 still recruiting?

NCT02695381 is currently completed. Last updated 8 September 2016.

Last reviewed 2016-09-08 · How we verify

NCT02695381

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-blind, Multiple-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Etodolac-lidocaine Patch Applied Once Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness

Completed Phase 3 Last updated 8 September 2016

What this trial tests

Phase 3 trial testing Etodolac-lidocaine topical patch in Acute Delayed Onset Muscle Soreness (DOMS) in 100 participants. Completed in 1 September 2016.

Timeline

1 March 2016

Primary endpoint
1 August 2016

1 September 2016

Quick facts

Lead sponsor	MEDRx USA, Inc.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	triple
Primary purpose	treatment
Enrollment	100
Start date	1 March 2016
Primary completion	1 August 2016
Estimated completion	1 September 2016
Sites	1 location across United States

Drugs / interventions tested

Etodolac-lidocaine topical patch — full drug profile →
Placebo

Conditions studied

Acute Delayed Onset Muscle Soreness (DOMS) — all drugs for Acute Delayed Onset Muscle Soreness (DOMS) →

Sponsor

MEDRx USA, Inc. — full company profile →

Who can join

Adults 18 to 35, any sex, with Acute Delayed Onset Muscle Soreness (DOMS). Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sum of the time-weighted differences from baseline in pain intensity with movement (SPIDMove) over 0-24 hours post-T0 (SPIDMove 0-24 hours).
Time frame: 24 hours

Sponsor's own description

This study evaluate the efficacy and safety of Etodolac-lidocaine topical patch applied one time daily when compared with placebo in the treatment of acute Delayed Onset Muscle Soreness (DOMS) of the upper limbs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02695381 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MEDRx USA, Inc.
Last refreshed: 8 September 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02695381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing